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The N-terminal structures of the MN and Ss erythrocyte membrane sialoglycoproteins (glycophorins A, B) 
from two Henshaw (He) blood-group heterozygotes were determined by manual sequencing of tryptic 
glycopeptides and various secondary fragments. No structural alteration of the M N  glycoprotein co+uld be de+tected. 
The He-specific portion of the Ss glycoprotein was found to exhibit the N-terminal sequence Trp-Ser-Thr-Ser-Gly- 
(+ = glycosylation). Thus it differs at  three positions from its normal counterpart which possesses ‘N’ activity and 
exhibits the N-terminal structure Leu-Sir-Thr-Thr-Glu-. Analysis of the Ss glycoprotein from 15 He-negative 
erythrocyte samples did not reveal any of the three He-specific structural alterations. The presence of a glycine 
residue at  the fifth position of the blood-group-M-active M N  glycoprotein as well as in the He-specific Ss 
glycoprotein provides an  explanation for the occurence of antisera (anti-Me) reacting with the M and He antigens. 
+ +  
Previous studies have provided evidence that the human 
MN and Ss blood-group gene loci encode the amino acid 
sequences of two (MN and Ss) sialoglycoproteins (SGPs) 
(synonyms : glycophorins A, B) in red blood cell membranes 
[I -41. Amino acid polymorphisms at the first (serinejleucine) 
and fifth (glycine/glutamic acid) positions of the major (MN) 
SGP determine M N  blood-group specificity [5 - 101, whereas 
the Ss antigens appear to be dependent on a methioninel 
threonine polymorphism at position 29 of the Ss SGP [ l l  
- 131. The N-terminal 26 residues of the Ss SGP are identical 
with those of the blood-group-N-active major glycoprotein [9 
- 121. Therefore, the former molecule carries an additional N 
receptor, denoted as ‘N’ [1,3]. 
The Henshaw (He) erythrocyte antigen, which occurs in 
about 5% of blacks and only rather rarely in Caucasians, is 
genetically associated with the MNSs receptors [ l ,  14 -171. 
Serological studies have revealed that certain rabbit or human 
antisera, denoted as anti-Me, react with the He and M 
antigens, suggesting that both receptors exhibit a structural 
similarity. In the present communication we describe studies 
on the SGPs from two He heterozygotes. Our data dem- 
Abbreviations. BNPS-skatole, 2-(2-nitrophenylsulfenyl)-3-methyl- 
3-bromoindolenine; dansyl-, l-(dimethylamino)naphthalene-5-sul- 
phonyl-; DABITC, 4-N,N-dimethylaminoazobenzene-4’-isothiocya- 
nate; DABTH, 4-N,N-dimethylaminoazobenzene-4’-thiohydantoin; 
PITC, phenylisothiocyanate; SGP, sialoglycoprotein. Peptides are 
designated according to the SGP (MN or Ss) from which they were 
derived by trypsin (T), chymotrypsin (C), V8 protease (V) (after 
desialylation (d)) or cyanogen bromide (B) treatment, the elution 
during gel filtration (1 etc.) and the MN or Ss blood type of the red 
cells. 
Enzymes. Neuraminidase, acylneuraminyl hydrolase (EC 3.2.1.18); 
trypsin (EC 3.4.21.4); chymotrypsin (EC 3.4.21.1); Staphylococcal V8 
protease (EC 3.4.21.19). 
-.____ 
onstrate that the He receptor represents an allelomorphic form 
of the ‘N’ antigen on the Ss SGP. 
MATERIALS A N D  METHODS 
Blood units from two unrelated, He heterozygous black 
donors (genotypes MSjNS or NSINs) were drawn in Ann 
Arbor and Houston. I t  could not be elucidated with which 
M N S s  haplotype He is associated. Blood samples from He- 
negative individuals were gifts of P. D. Issitt (South Florida 
Blood Service, Miami), P. Harris (American Dade Corpora- 
tion, Miami) and S. Wilkinson (P. Hoxworth Blood Center, 
University of Cincinnati) or obtained in Houston and Cologne. 
Anti-He was detected in the serum of a blood donor at Gamma 
Biological Inc. (Houston). BNPS-skatole was purchased from 
Pierce Chem. Corp. (Rockford, USA). Other materials have 
been described in previous publications [3,7 -9,31,12,18 -221. 
Analytical procedures 
Sialic acid, protein and sodium dodecylsulfate/polyacryl- 
amide gel electrophoretic analyses were performed by the 
methods of Warren [23], Lowry et al. [24] and Laemmli 
[22,25], respectively. Amino acids and amino sugars were 
determined on automated amino acid analyzers [18,20]. Data 
on amino acids given in tables is uncorrected; values of the 
amino sugars were corrected for destruction during hydrolysis, 
using N-acetylaminosugars as standards. Tryptophan was 
measured spectrofluorometrically [lo]. Manual sequence ana- 
lyses of peptides were performed by the DABITCiPITC 
double-coupling method [ 12,26,27] and dansyl-techniques 
[28,29]. Conversion of the thiazolinones to DABTH-deriva- 
tives was carried out in aqueous trifluoroacetic acid (2 : 1 ; vjv) 
at 52°C for 50 min. Direct identification of glycosylated 
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DABTH-serine or DABTH-threonine at certain positions of 
peptides was performed by analyses of the aqueous phases 
after butyl-acetate extraction, as $scribed previously [20]. 
For haemagglutination assays, a 5/0 suspension of red cells 
(20 pl) was incubated with an equal volume of serial twofold 
dilutions of serum prepared with saline (0.145 M) solution. 
Results were read macroscopically after 30min at room 
temperature and centrifugation in a Sorvall CW-1 centrifuge. 
For inhibition tests, agglutinin (20 pl; titre 1 :4) was incubated 
for one hour at room temperature with 20 pl of serial twofold 
dilutions of the inhibitor solution (10 mgiml), before the 
erythrocyte suspension (20 pl) was added. 
Preparation o j  red cells: membranes, SGPs and peptides 
Red cell membranes were extracted by the phenol/saline 
method [I91 and the SGP mixture was fractionated into the 
major (MN) glycoprotein and the mixture of minor SGPs by 
gel filtration in the presence of detergent [7 -91. N-terminal 
glycopeptides of the MN and Ss SGPs were purified by gel and 
DEAE-cellulose chromatography after tryptic digestion of the 
SGP fractions [I0 - 12,301. Secondary chymotryptic and V8 
protease peptides were prepared after desialylation by mild 
acid hydrolysis and separated by gel filtration [12,20,30]. The 
mixture (T1/2) of the two N-terminal peptides NNTl (residues 
1 - 39) and NNT2 (residues 1 -31) from the MN SGP [lo, 301 
of the He + NNSs donor and the mixture of the secondary V8 
protease fragments (fraction SsTldVl ; residues 1 - 28 and 
6-28) from the Ss SGP of the He + MNSS donor, after 
reduction, were cleaved with cyanogen bromide for 7 h and 
24 h, respectively [I 1,12,30]. Treatment of intact erythrocytes 
with neuraminidase, trypsin or a-chymotrypsin was performed 
as described elsewhere [3,19]. N-Acetylation and desialylation 
(mild acid hydrolysis) of SGPs were carried out as in a previous 
paper [20]. For BNPS-skatole treatment [32], 5 mg of SGPs 
were incubated with 10 mg of the reagent in 1 ml of 80% (v/v) 
acetic acid for 5 h at room temperature. Subsequently, the 
sample was reduced with thioglycolic acid [31]. All modified 
SGPs were recovered by gel filtration on acolumn of Sephadex 
G-25 1311 and lyophilization. 
RESULTS 
Sialic acid, gel electrophoretic and serological analyses 
The sialic acid levels of membranes from the two He- 
positive red cell samples (102% and 96% for the MSjNS  and 
the NSjNs donor, respectively) were not significantly different 
from those of control ghosts possessing identical Ss blood 
types (SS membranes, 100% f7%, n = 3 ;  Ss membranes, 
100% k 6%, n = 3) [4,8]. Sodium dodecylsulfate/polyacryl- 
amide gel electrophoresis of the He-erythrocyte membranes, 
followed by staining for protein or carbohydrate, revealed 
normal patterns. The periodic acid/Schiff-staining intensities 
of the SGP bands were not significantly different from those of 
control ghosts run simultaneously (data not shown). 
Treatment of intact erythrocytes with a-chymotrypsin 
removes the N-terminal, glycosylated domain of the Ss SGP, 
whereas trypsin has no significant effect on this molecule. The 
N-terminal portion of the MN SGP is partially or completely 
released by chymotrypsin or trypsin, respectively [3,30]. The 
reaction of anti-He was slightly enhanced after trypsin treat- 
ment and weakened or abolished after a-chymotrypsin or 
neuraminidase digestion, respectively, of intact red cells 
(Table 1). This suggests that the He-receptor is located on the 
glycosylated portion of the Ss SGP. 
Table 1. Agglutination of enzyme-treuted H e  + MNSS red cells 
by anti-He 
g = n o  agglutination by undiluted serum 
Agglutination titre with treatment by 
None trypsin r*-chymotrypsin neuraminidase 
~~ ~ ~~ ~- ~~~~~ 
~ 
1 :8 1 :16 1 :2 Q 
Table 2. Inhibition of anti-He by SGP jkactions and ,fragments ,from 
He  + M N S S  red cells 
The unfractionated SGP mixture treated by acetylation, mild acid 
hydrolysis or BNPS-skatole was inactive at 10 mg/ml 
Inhibitor Inhibitory activity 
mg/ml 
Unfractionated SGP mixture 0.6 
M N  SGP > 10.0 
Minor SGP mixture 0.15 
> 10.0 
SsTl (residues 1-32) 0.3 
MNT1/2 (residues 1 -39/31) 
Anti-He was found to be inhibited by the unfractionated 
SGP mixture from He-erythrocytes (Table 2), which con- 
tained the MN SGP, Ss SGP and D SGP (= glycophorin C) 
in a ratio of about 1.0:0.2:0.1, as judged from periodic 
acid/Schiff-staining after sodium dodecylsulfate/polyacryl- 
amide gel electrophoresis. The antigen activity was enriched in 
the minor SGP fraction, prepared by gel filtration [9], which 
predominantly (ca. 65%) contained the Ss SGP, apart from 
other glycoproteins (MN SGP ca. 5 % ,  D SGP ca. 20% and 
additional minor bands, see [9]), as revealed by electrophoretic 
analysis. The N-terminal peptide (SsT1, residues 1 - 32) of the 
Ss SGP, purified after tryptic digestion of the mixture of minor 
SGPs [I 0,l  I ]  also inhibited anti-He. Treatment with BNPS- 
skatole, desialylation and N-acetylation of SGPs destroyed 
their He-activity, suggesting that tryptophan, sialic acid(s) and 
amino group(s) are involved in the binding site of anti-He. 
Structural analyses of glycopeptides 
In view of the known antigenic relationship between the M 
and He antigens [16,17]. the mixture (T1/2, residues 1 -39/31) 
of the two N-terminal tryptic glycopeptides (TI, residues 
1 -39; T2, residues 1 -31 [10,30]) were prepared from 
the major SGP of both He erythrocyte samples. T1/2 frag- 
ments from the He + MNSS individual were further digested 
by V8 protease after desialylation. Glycopeptides from the He 
+ NNSs donor were cleaved with cyanogen bromide. Amino 
acid analyses of all these fragments (Table 3), performed in 
comparison to corresponding peptides from He-negative red 
cells (data not shown), did not reveal any alteration. In 
addition, sequence analyses (see legend to Table 3) did not 
provide any evidence for an amino acid exchange. 
The N-terminal tryptic peptide (SsT1, residues 1 -32), 
presumed to carry the He antigen, was also isolated from the 
red cells of both He-heterozygotes. The normal, "'-active Ss 
SGP exhibits glutamic acid as the fifth residue. Therefore, it 
can be cleaved by V8 protease at this position after desialyla- 
tion [12]. Analyses on the SsTl preparations from the two He- 
heterozygotes (see below) revealed a glutamic acid and a 
glycine residue at the fifth position and two additional amino 
acid exchanges at the first and fourth positions. Therefore, 
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Table 3. Amino ucid compositions gjpeptides MNTIl2 and “TI12 f rom He erythrocytes and secondary V8 protease or cyanogen-bromide 
fragments 
Values are expressed as residues per peptide molecule. A dash denotes less than 0.1 residue. Sequence analyses by the DABITC/PITC method (10, 
16,4, 14 and 7 degradation cycles for the peptides T1/2, NNT1/2dV1, MNT1/2dV2, MNT1/2B1 and NNT1/:2B2, respectively) did not provide 
any evidence for an amino acid substitution. GalNH, galactosamine ; GlcNH, , glucosamine, Hse, homoserine 
Amino acid Peptide and position 
~~~~ ~ ~~~ ~~ ~~~ . ~ ~~~ ~~~ 
MNTl / 2  MNTl i2dV1 MNTl j2dV2 “TI12 NNT li2B1 NNT112B2 
1-39/31 116 - 39/31 1-5 1-39/31 9 - 39/31 1-8 
2.6 2.6 - 2.6 2.4 - ASP 
Thr 1.7 6.8 2.0 8.3 5.9 2.3 
Ser 7.9 7.0 0.9 7.9 6.7 1 .0 
Glu 1.6 1.2 1.1 2.3 1.3 0.9 
Pro 0.4 0.3 0.5 0.4 - 
GlY 0.6 0.6 - 0.1 
Ala 1.9 1.7 0.1 1 .Y 0.9 1 .0 
Val 2.1 2.0 - 2.0 1.2 1 .0 
Met 1.1 1 .0 - 0.9 
Ile 1 .0 1 .0 - 1 .0 1 .0 
Leu 0.6 - 0.9 1.0 0.1 1 .o 
1.1 1.1 - 1.4 1.2 
His 2.1 1.8 - 2.0 1.9 
TYr 
2.1 1 . Y  2.1 2.0 - LYS 




GalNH, 11.5 10.6 3.0 11.6 8.7 3.0 









- - - - - 
desialylated SsTl (residues 1-32) from both donors was 
digested with V8 protease, in order to selectively release a 
N-terminal pentapeptide (HeSsTldV2, residue 1 - 5) from 
the normal, “’-active peptide portion. Subsequent gel filtra- 
tion yielded one fraction (HeSsTldVl, residues 1/6 -28) 
containing a mixture of two fragments (He-specific portion, 
residues 1-28; normal portion, residues 6-28). Analysis of 
fraction HeSsTl dV1 (residues 1/6 -28) established that all 
three amino acid exchanges (see below) occur in one (the He- 
specific) portion of the peptides from the He-heterozygotes. 
Peptide fraction HeSsTlVl (residues 1/6-28) from the He 
+ M N S S  donor was further cleaved with cyanogen bromide, 
in order to obtain a small fragment (HeSsTldVIB2, residues 
1-8) from the N-terminal end of the He-specific portion of 
SsTl (residues 1 -32). Desialylated SsTl from that individual 
was also digested with chymotrypsin, in order to obtain 
additional fragments for sequencing. Amino acid analyses of 
all the fragments described above are shown in Table 4. As can 
be seen from the composition of SsTl (residues 1 -32), this 
fragment was predominantly or exclusively released by clea- 
vage at residue 32, rather than at position 35 [12], probably due 
to chymotryptic activity in the trypsin preparation. As judged 
from the data in Table 4 and comparative analyses of glyco- 
peptides from He-negative erythrocytes (data not shown), the 
He-specific SsTl portion exhibits three amino acid sub- 
stitutions within the N-terminal eight residues. No significant 
change in the degree of glycosylation was apparent from 
galactosamine analyses. 
Sequencing data on the various fragments described above 
are summarized in Fig. 1. The He-specific portion of SsTl 
(residues 1 -32) was found to exhibit leucine+tryptophan, 
threonine-tserine and glutamic aciddglycine substitutions at 
the first, fourth and fifth positions, respectively. As shown in 
Fig. 1, the threonine-tserine exchange was not detected by the 
initial sequencing of SsTl. A glycosylated serine occurring 
together with a threonine is difficult to detect [12,26]. 
Furthermore, only a small amount of SsTl was used for 
sequencing, in order to preserve material for the preparation of 
secondary peptides. 
Previous sequence analyses of the N-terminal portion of 
the Ss SGP had been exclusively performed on proteins or 
peptides, pooled from several individuals [9 - 121. Peptide 
SsTl (residues 1 - 32/35) was therefore isolated from 15 He- 
negative donors (seven blacks and eight Caucasians). The N- 
terminal five residues were investigated by DABITCjPITC 
sequencing; the fourth position was also determined by the 
dansyl-technique. None of the three He-characteristic amino 
acid substitutions could be detected. 
DISCUSSION 
Our serological data demonstrate that the He antigen is 
associated with the N-terminal glycopeptides (SsT1, residues 
1 -32) of the Ss glycoprotein, for which leucine-ttrypto- 
phan, threonine-tserine and glutamic acid-tglycine ex- 
changes were detected at the first, fourth and fifth positions, 
respectively. Destruction or He activity by chemical modifi- 
cation of SGPs suggests that the antigen is located in that 
region of the fragment. The He receptor is apparently coded 
for by an allele of ‘ N ’ ,  the specificity of which is determined by 
leucine and glutamic acid at the first and fifth positions, 
respectively, of the Ss SGP. Further evidence for this con- 
clusion has been obtained by recent studies on an individual 
who possesses the rare genotype MFIMsHe and whose red 
cells are devoid of ‘N’ antigen. An allo-anti-N made by this 
individual is directed against blood-group-N-active N-termi- 
nal octaglycopeptides [33]. 
Previous studies have shown that the receptors of many 
anti-M or anti-N sera are destroyed by the removal of sialic 
acid(s), attached to oligosaccharide(s) at the second, third 
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Table 4. Amino acid compositions ofpeptides SSTl and SsTl f rom H e  erythrocytes andsecondary VXprotease, cyanogen-bromide or chymotryptic 
fragments 
For simplification the compositions of the V8 protease peptides from the He + NNSs donor are not shown. For further details see Table 3 
Amino Peptide and position 
acid ~~- - _ ~  ~~ ~ ~ _ _  _
SsTl SSTl SSTldCl SSTldC2 SSTldVl SSTldV2 SSTldV3 SSTldVlBl SSTldVlB2 SSTldVlB3 



















1.2 1.1 0.1 
5.1 5.4 4.2 
8.0 8.2 6.1 
3.5 3.5 0.6 
2.5 2.6 0.6 
1.1 1.1 1.0 
2.0 2.1 2.0 
1.5 1.9 0.9 
1.0 1.0 - 
1.5 1.6 0.6 
1.0 1.1 0.9 
1.1 1.2 1.0 
1.1 1.0 0.9 
0.1 0.2 - 
+ + + 
11.8 11.1 8.6 
- - - 
































































































N-terminal structure of blood group M-active MN SGP 
* * *  * * * * * I  * * * *  * *  
S-S-T-T-G-V-A-M-H-T-S-T-S-S-S-V-T-K-S-Y-I-S-S-Q-T-N-D-T-H-K-R-D- 
N-terminal structure of blood group "'-active Ss SGP 
* * *  * * * * * *  * * * *  * 
L-S- T- T-E-V- A-M-H- T- S- T- S- S- S-V- T-K- S-Y- I-S- S- Q- T-N-G-E-~- G- Q- L- T 
Proposed structure of He-specific SsTl 
* * * * * *  * * * *  * 
M 
T 
* * *  
W-S-T-S-G-V-A-M-H-T-S-T-S-S-S-V-T-K-S-Y-I-S-S-Q-T-N-G-E- -G-Q-L 
1 10 20 70 32 
Sequencing results and alignment of secondary peptides 
SsTldVlB2 (1-8) SsTldVlBl (9-28) SsTldVlB3 (6-8) 
W-S-T-S-G-V-A-b)H-T-S-T-s-s-s-v-T-K-s-y-I-s-s-a) - - -  V-A-0) + + +  
Fig. 1. Amino acid sequence of He-specific SsTl, deduced f rom analyses of He-lzeterozygotes. The N-terminal structures of the b1ood-group-M- 
active MN SGP and the normal, blood-group-"'-specific Ss SGP are shown for comparison. The one-letter code for amino acids has been used 
[32]. (a) = sequence representing the He-specific and "'-specific peptide portion, (b) = sequence corresponding to the He-specific peptide 
portion, (c) = sequence representing the "'-active peptide portion (not aligned below the proposed structure of the He-specific SsT1). * denotes a 
glycosylation site. Unless otherwise indicated, amino acids were identified as DABTH derivatives. - =identification as DABTH and dansyl 
derivative, =identification as dansyl derivative, + =direct identification of a glycosylated residue by analysis of the aqueous phase after butyl- 
acetate extraction [20] 
and/or fourth position(s) of the SGPs [1,6,9,21,34]. Sialic 
acid(s) might represent a direct part of these antigenic 
determinants or stabilize a particular conformation of the N- 
terminal region of the SGPs, necessary for the binding of 
antibodies. The anti-He, which we have employed, is com- 
parable to sialic acid-dependent anti-M or anti-N sera, since it 
did not react with desialylated red cells or SGPs. Samples of 
anti-He, which do not require sialic acid(s), have also been 
described [34]. 
The N-terminal tryptophan is apparently important for He 
activity, as measured with the single sample of anti-He which 
we have used. However, the significance of the serine and 
glycine residues at the fourth and fifth positions, respectively, 
is not clear. Given the polyclonal nature of antibodies, anti-He 
sera might require only one or two or all three of the He- 
specific amino acid exchanges. Since no structural alteration 
could be detected for the N-terminal region of the MN SGP 
from He-erythrocytes, the presence of a glycine residue at the 
fifth position of the blood group M-specific major SGP as well 
as in the He-active Ss SGP may account for the occurrence of 
antibodies (anti-Me) reacting with both antigens [16,17]. 
Apparently, such antibodies do not distinguish between serine 
or tryptophan and threonine or serine at the positions one and 
four, respectively. 
The two amino acid polymorphisms which represent the 
structural difference between MN antigens on the major SGP 
can be attributed to a minimum of two DNA base exchanges. 
Evidence has been obtained that the evolutionary develop- 
ment of the N antigen from the M receptor occurred via a rare 
gene encoding the M"-specific amino acid sequence [35,36]. 
Similarly, the three He-characteristic structural alterations 
described above might be attributed to three independent 
amino acid and DNA base exchanges which had occurred 
sequentially during evolution. If this were so, two intermediate 
amino acid sequences should occur. In view of the uncertainty 
about the specificity of anti-He, discussed above, and the 
limited number of He-positive and He-negative erythrocytes 
which we have investigated by structural analyses, it is at 
present impossible to decide whether or not such intermediate 
amino acid sequences exist. When one of the possible mRNA 
sequences (UUG-UCU-ACA-ACU-GAG) coding for the N- 
terminal five residues of the N-active Ss SGP is read in the 
reversed direction, the sequence Ser2-Thr3-Thr4 can be con- 
verted into Ser2-Thr3-Ser4. The change from Leu' and Glu5 
into Gly5 and Trp', respectively, requires three additional base 
exchanges (mRNA sequence UGG-UCA-ACA-UCU-GGU). 
Therefore, it is also conceivable that the He-specific structure 
evolved from an inversion of this gene segment. Development 
of the He-active Ss SGP by an inversion plus one DNA base 
exchange and unequal cross over of a gene encoding a M- 
specific MN SGP would also be possible. 
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